Monitoring Patients On Tki's

Monitoring Patients on TKI's

The Importance of Monitoring Patients on TKIs

TKI-related toxicities in CML & the importance of long-term monitoring

VJHemOnc – Video Journal of Hematology & HemOnc

Real-world analysis: molecular monitoring and adherence patterns to TKIs in older patients with CML

VJHemOnc – Video Journal of Hematology & HemOnc

Outcomes of patients with CML with no molecular response within two years of TKI therapy

VJHemOnc – Video Journal of Hematology & HemOnc

Response Monitoring of Patients With CML Treated With TKIs

Targeted Oncology

MASSIMO BRECCIA, ASH 2019: DISCONTINUING TKIs IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

Touch Medical Media

Case 3: TKI Therapy and Treatment Monitoring in CML

Targeted Oncology

Access to CML Monitoring and Treatment is Changing Lives Around the World

Outcomes of patients with CML-CP treated with ponatinib vs 2G-TKIs in the third-line setting

VJHemOnc – Video Journal of Hematology & HemOnc

Patient Monitoring in Chronic Myeloid Leukemia (CML)

Monitoring Patients on Second-Generation ALK Inhibitors

Targeted Oncology

Managing adverse events associated with TKIs in CML

VJHemOnc – Video Journal of Hematology & HemOnc

Monitoring Response to CML Therapy

Update on the efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukemia

VJHemOnc – Video Journal of Hematology & HemOnc

Which TKI is Best for Me? / CML / TKI / Chronic Myeloid Leukemia / Tyrosine Kinase Inhibitor

Dr. Michael Mauro on Toxicities of TKI Usage in CML Patients

Targeted Oncology

Achieving successful TFR in CML & recommendations for monitoring after treatment discontinuation

VJHemOnc – Video Journal of Hematology & HemOnc

Interim Data Analysis Suggests Ponatinib to be Favorable TKI Treatment Among CML Patients

Phamacology monitoring and drug-drug interactions in older patients with cancer